111In-Panitumumab

panitumumab (Indium-111 radiolabeled) · Amgen

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 111In-Panitumumab, covering 2025-12-24 to 2025-12-24. Get the full timeline:

Most recent: Clinical Trial Update: Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer [Phase 1]